Pha for aplastic anemias: The alpha but not the omega of mitogen therapies

Cancer Biotherapy and Radiopharmaceuticals

Volumn 13, Issue 2, 1998, Pages 109-120

  Wimer, Bruce M ^a  

^a JBMW Immunotherapeutics   (United States)

Author keywords

Aplastic anemias; Canine glioma; Con A; IL 1; Immunostimulation; Immunosuppression; Mast cells; Neoplasms; PHA; Plant mitogens; PWM; Stem cell factor; TNF alpha

Indexed keywords

CONCANAVALIN A; INTERLEUKIN 1; MITOGENIC AGENT; PHYTOHEMAGGLUTININ; POKEWEED MITOGEN; STEM CELL FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APLASTIC ANEMIA; ARTICLE; CELL GRANULE; CLINICAL ARTICLE; CYTOTOXICITY; FEMALE; GLIOMA; HEMATOPOIESIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MALE; MAST CELL DEGRANULATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0031969242     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1998.13.109     Document Type: Article

References (47)

1. Wimer BM. Immunosuppressive applications of PHA and other plant mitogens. Cancer Biotherapy and Radiopharmaceuticals 1998;13:99-107.
2. Humble JG. In vivo action of phytohaemagglutinin in severe human aplastic anaemia. Nature 1963;196:1313-1314.
3. Humble JG. The treatment of aplastic anaemia with phytohaemagglutinin. Lancet 1964;1:1345-1349.
4. Wimer BM. Therapeutic activities of PHA-L4 the mitogenic isolectin of phytohemagglutinin. Molecular Biotherapy 1990;2:74-90.
5. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997;19:1365-1372.
6. Mann PL, Eschima D, Bitner DM, Griffey RH, Wenk R, Born JL, Matwiyoff NA. Biomodulation: An integrated approach to access and manipulate biological information. In: Gabius H-J, Gabius S (eds): Lectins and Cancer. Berlin-Heidelberg-New York-Tokyo, Springer-Verlag, 1991; 179-206.
7. Humble JG. The use of phytohaemagglutinin in the treatment of aplastic anaemia. In: Elves MW, (ed): The Biological Effects of Phytohaemagglutinin . Oswestry, England, The Robert Jones and Agnes Hunt Orthopaedic Hospital Management Committee, 1966;227-235.
8. Fleming AF. Letters to the Editor. Phytohaemagglutinin. Lancet 1964;2:647-648.
9. Retief FP, Wassermann HP, Hofineyer NG. Phytohaemagglutinin in aplastic anaemia. Lancet 1964;2:1343-1344.
10. Astoldi G, Airò R, Sauli S, Costa G. Phytohaemagglutinin in the treatment of aplastic anaemia. Lancet 1965;1:1070-1071.
11. Gurling KJ, Leonard BJ. Phytohaemagglutinin in aplastic anaemia. Lancet 1965;2:794.
12. Baker GP, Oliver RAM. Phytohaemagglutinin in the treatment of aplastic anaemia. Lancet 1965;1:438.
13. Gruenwald H, Taub RN, Wong FM, Kiossoglou KA. Phytohaemagglutinin in treatment of aplastic anaemia. Lancet 1965;1:962.
14. Mehra SK, Davies DM, Bell SM. Phytohaemagglutinin in the treatment of aplastic anaemia. Lancet 1965;1:1164-1165.
15. Aksoy M, Erdem S, Dincol K. Phytohaemagglutinin in refractory anaemia. Lancet 1966;2:1464-1465.
16. Buschor OR, von Deschwanden PL. Phytohaemagglutinin in aplastic anaemia. Lancet 1966; 1:770-771.
17. Fleming AF, Osunkoya BO, Antia AU. Phytohaemagglutinin in aplastic anaemia. Lancet 1966;2:338-339.
18. Hayes DM, Spurr CL. Use of phytohemagglutinin to stimulate hematopoiesis in humans. Blood 1966;27:78-84.
19. Thiele HG, von Wiehert P. Phytohaemagglutinin in aplastic anaemia. Lancet 1967;1:1003.
20. Catovsky D, Sforza MB. Phytohaemagglutinin in aplastic anaemia. Lancet 1967;2:991-992.
21. Allison A, Hume R, Shaw G, Whitelaw J, Willoughby M. Phytohaemagglutinin in refractory anaemia. Scot Med J 1965;10:461-465.
22. Morstyn G, Burgess AW. Hemopoietic growth factors: a review. Cancer Res 1988;48:5624-5637.
23. Wimer BM. Therapeutic immunostimulating effects of plant mitogens exemplified by the L4 isolectin of PHA Cancer Biotherapy and Radiopharmaceuticals 1997;12:195-212.
24. Lewis MG, Humble JG, Lee ES, Phillips TM. The effects of intravenous phytohaemagglutinin in a patient with disseminated malignant melanoma. A clinical and immunological study. Rev Europ Etudes Clin Biol 1971;16:924-927.
25. Champlin R, Feig SE, Sparkes RS, Gale RP. Bone marrow transplantation from identical twins in the treatment of aplastic anaemia: implication for the pathogenesis of the disease. Br J Haematol 1984;56:455-463.
26. Mathé G, Amiel JL, Schwarzenberg L, Choay J, Trolard P, Schneider M, Hayat M, Schlumberger JR, Jasmin CI. Bone marrow graft in man after conditioning by antilymphocytic serum. BMJ 1970;2:131-136.
27. Speck B, Gluckman E, Haak HL, van Rood JJ. Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone marrow infusions. Lancet 1977;2:1145-1148.
28. Champlin RE, Ho W, Gale RP. Antilymphocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med 1983;308:113-118.
29. Wimer BM, Morris RE. Theoretical benefits of mitogen applications for HIV-1 infections. Cancer Biotherapy and Radiopharmaceuticals 1997;12:213-222.
30. Wimer BM. The ideal biological response modifier. Molecular Biotherapy 1989;1:311-317.
31. Wimer BM. Characteristics of PHA-L4 the mitogenic isolectin of phytohemagglutinin as an ideal biological response modifier. Molecular Biotherapy 1990;2:4-17.
32. Glad C, Borrebaeck CAK. Affinity of phytohemagglutinin (PHA) isolectins for serum proteins and regulation of the lectin-induced lymphocyte transformation. J Immunol 1984;133: 2126-2132.
33. Waxdal MJ. Isolation, characterization, and biological activities of five mitogens from pokeweed. Biochem 1974;13:3671-3677.
34. Wimer BM. Haplotype donor-generated graft-versus-leukemia responses: Serendipity revisited. Cancer Biotherapy 1995;10:181-94.
35. Wimer BM. Putative effects of mitogenic lectin therapy corroborated by alloactivation data. Cancer Biotherapy and Radiopharmaceuticals 1996;11:57-75.
36. Fames P, Barker BE, Brownhill LE, Fanger H. Mitogenic activity in Phytolacca americana (pokeweed) Lancet 1964;2:1000-1101.
37. Barker BE, Fames P, Fanger H Mitogenic activity in Phytolacca americana (pokeweed) Lancet 1965;1:170.
38. Barker BE, Farnes P, LaMarche PH Peripheral blood plasmacytosis following systemic exposure to Phytolacca americana (pokeweed). Pediatrics 1966;38:490-493.
39. Wimer BM . The rationale of mitogen lectin therapy for cancer. In: Gabius H-J, Gabius S (eds): Lectins and Cancer. Berlin-Heidelberg-New York-Tokyo, Springer-Verlag, 1991;217-228.
40. Bitner DM, Mann PL, D'Souza P, Wenk R, Baughman DG, Quesada R, Purvis R, Born JL, Matwioff N, Eshima D. Enhanced tumor imaging with pokeweed mitogen. In: Eckelman (ed) Nuclear Medicine and Biology. Oxford-New York-Seoul-Tokyo, Pergamon Press, 1993; 203-210.
41. Jadus MR, Schmunk G, Djeu JY, Parkman R. Morphology and lytic mechanisms of interleukin 3-dependent natural cytotoxic cells. tumor necrosis factor as a possible mediator. J Immunol 1986;137:2774-2783.
42. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 1990;346:274-276.
43. Broudy VC. Stem cell factor and hematopoiesis. Blood 1997;90:1345-1364.
44. Rosenau W, Habler J, Goldberg M. Prolongation of skin graft survival by administration of purified phytohemagglutinin. Transplantation 1972;13:624-626.
45. Goldberg ML, Rosenau W, Burke GC. Fractionation of phytohemagglutinin, I. Purification of the RNA and DNA synthesis-stimulating substances and evidence that they are not proteins. Proc Nat Acad Sci 1969;64:283-289.
46. Rigas DA, Tisdale VV. Bioassay and dose-response of the mitogenic activity of the phytohemagglutinin Phaseolus vulgaris. Experientia 1969;25:399-400.
47. Goldberg ML, Rosenau W, Burke GC, Moon HD. Dose-response of lymphocytes to purified, protein-free phytohemagglutinin: Lack of metabolic inhibition with increasing concentrations. Proc Soc Exp Biol Med 1970;13-459-461.